Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Cullinan Therapeutics Inc (CGEM)

170 + Investors. Track Smart Money conviction in CGEM. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +19
Streak
3Q ▲
Buyers last Q
62%

Smart Money Signals — CGEM

Based on 171 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added CGEM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
171 hedge funds hold CGEM right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +16% more funds vs a year ago

fund count last 6Q
+23 new funds entered over the past year (+16% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟢

More buyers than sellers — 62% buying

99 buying61 selling
Last quarter: 99 funds were net buyers (38 opened a brand new position + 61 added to an existing one). Only 61 were sellers (42 trimmed + 19 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+8 vs last Q)

new funds entering per quarter
Funds opening a new CGEM position: 19 → 27 → 30 → 38. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

43% of holders stayed for 2+ years

■ 43% conviction (2yr+) ■ 25% medium ■ 32% new
73 out of 171 hedge funds have held CGEM for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +37% but shares only +3% — price-driven

Value
+37%
Shares
+3%
Last quarter: the total dollar value of institutional holdings rose +37%, but actual share count only changed +3%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

27 → 19 → 27 → 30 → 38 new funds/Q
New funds entering each quarter: 19 → 27 → 30 → 38. A growing number of institutions are discovering CGEM each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Deep conviction — 51% of holders stayed 2+ years

■ 51% veterans ■ 17% 1-2yr ■ 32% new
Of 175 current holders: 89 (51%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
📋

Smaller funds dominant — 17% AUM from top-100

17% from top-100 AUM funds
39 of 171 holders rank in the top 100 by AUM, but together hold only 17% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
4.0
out of 10
Moderate Exit Risk
Exit risk score 4.0/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CGEM

In 2026 Q1, 99 hedge funds were net buyers of CGEM (38 opened a new position, 61 added to an existing one), while 61 reduced or exited (42 trimmed, 19 sold completely) — a 62% buyer ratio, indicating clear institutional accumulation. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. Net fund flow last quarter: +19 funds (more new holders than closures). Total institutional holders: 171.

Hedge Fund Ownership: CGEM

How many hedge funds hold CGEM — quarterly history vs. share price
Quarterly hedge fund ownership of CGEM vs. share price

Market Analysis: CGEM

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CGEM

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Cullinan Therapeutics Inc (CGEM) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CGEM has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 76d ago
CGEM
-3.9%
XLV
+4.6%

CGEM outperformed XLV by -8.5% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 31d ago
CGEM
-13.2%
XLV
+5.6%

Since the filing became public, CGEM outperformed XLV by -18.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

19 top-rated funds 0 high-conviction
Consensus
5.6
/ 10
breadth
×
Elite
1.9
/ 10
conviction
Hedge Fund Positioning: CGEM
170 + Investors

Track Smart Money conviction in CGEM. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 170 152 11.84%
13F Shares 66M 64M 3.32%
Total Value $901M $657M 37.08%
New Positions 37 30 +7
Increased Positions 60 64 -4
Closed Positions 19 22 -3
Reduced Positions 40 41 -1
Total Calls 3 3 -
Total Puts 1 2 -50.0%
PUT/CALL Ratio 0.33 0.67 Bullish

Statistics: CGEM

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

170 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CGEM. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CGEM holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Lynx1 Capital Management LP 20.13% 8,963,500 $127.4M
2 MPM BioImpact LLC 8.39% 7,648,268 $108.7M
3 Blue Owl Capital Holdings LP 7.29% 1,909,764 $27.1M
4 Kynam Capital Management, LP 2.73% 3,114,132 $44.3M
5 Bvf Inc/Il 2.60% 5,750,683 $81.7M
6 Elmind Capital, LP 2.14% 530,000 $7.5M
7 Nextech Invest, Ltd. 1.14% 1,141,145 $16.2M
8 Great Point Partners LLC 0.98% 300,000 $4.3M
9 Twin Focus Capital Partners, LLC 0.97% 595,489 $8.5M
10 Venrock Adviser, LLC 0.73% 1,379,965 $19.6M
11 Superstring Capital Management LP 0.60% 59,484 $845K
12 Affinity Asset Advisors, LLC 0.57% 781,260 $11.1M
13 Siren, L.L.C. 0.47% 1,193,410 $17.0M
14 PFM Health Sciences, LP 0.29% 227,406 $3.2M
15 AlphaCentric Advisors LLC 0.29% 20,135 $286K
16 Bleichroeder LP 0.25% 100,000 $1.4M
17 Rtw Investments, LP 0.24% 1,705,960 $24.2M
18 Soleus Capital Management, L.P. 0.24% 410,200 $5.8M
19 Boothbay Fund Management, LLC 0.20% 1,112,803 $15.8M
20 Knott David M Jr 0.20% 24,200 $344K
21 Verdad Advisers, LP 0.20% 12,604 $179K
22 Optimize Financial Inc 0.20% 28,158 $400K
23 TCG Crossover Management, LLC 0.17% 406,786 $5.8M
24 Birchview Capital, LP 0.16% 20,000 $284K
25 Apis Capital Advisors, LLC 0.13% 60,000 $853K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Cullinan Therapeutics Inc (CGEM)

What does the Smart Money Trend signal show for CGEM?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added CGEM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CGEM?

More buyers than sellers — 62% buying: Last quarter: 99 funds were net buyers (38 opened a brand new position + 61 added to an existing one). Only 61 were sellers (42 trimmed + 19 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CGEM holders?

Smaller funds dominant — 17% AUM from top-100: 39 of 171 holders rank in the top 100 by AUM, but together hold only 17% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held CGEM?

43% of holders stayed for 2+ years: 73 out of 171 hedge funds have held CGEM for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Cullinan Therapeutics Inc (CGEM) following the 2026 Q1 hedge fund 13F filings?

As of today, CGEM has moved -13.2% since the 2026 Q1 13F filing date (May 15, 2026), compared to +5.6% for the XLV sector ETF — an outperformance of -18.8%. Since the quarter end (March 31, 2026), CGEM has gained -3.9% vs +4.6% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →